Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spyre Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing extended half-life antibodies for inflammatory bowel disease and rheumatic diseases. Its 8-K reports furnish financial results, Regulation FD clinical presentations, and material-event disclosures tied to SPY001, SPY002 and SPY003, including SKYLINE and SKYWAY program updates.
Offering-related filings describe common-stock issuance activity, underwriting agreements, shelf-registration use, proceeds for clinical development, manufacturing and general corporate purposes, and the company’s listed common stock. Proxy materials cover board and compensation matters, equity awards and public-company governance, while periodic and event reports address liquidity, research and development spending, clinical-trial risks and capital-structure disclosures.
Spyre Therapeutics (SYRE) is offering 14,864,865 shares of common stock at $18.50 per share. The deal implies $275,000,002 in gross proceeds, underwriting discounts of $16,500,000, and estimated net proceeds of about $257.7 million after expenses. Underwriters have a 30‑day option to purchase up to 2,229,729 additional shares.
The company plans to use proceeds to advance programs in inflammatory bowel disease and rheumatic diseases, including preclinical work, clinical trials, manufacturing, and Phase 3 readiness, plus working capital and general corporate purposes. Shares trade on Nasdaq as SYRE; the last reported price was $18.92 on October 13, 2025. Delivery of shares is expected on or about October 15, 2025.
The filing highlights dilution to new investors of $9.02 per share based on the pro forma as‑adjusted net tangible book value analysis. As context, the company preliminarily reported $486.2 million in cash, cash equivalents and marketable securities as of September 30, 2025.
Spyre Therapeutics (SYRE) launched a primary offering of common stock and, in lieu of shares for certain investors, pre-funded warrants under its effective Form S-3 shelf. The company will receive the proceeds and has also granted underwriters an option to purchase additional shares within 30 days. The pre-funded warrants have a $0.0001 per-share exercise price and include beneficial ownership limits.
Spyre plans to use proceeds to advance its IBD and rheumatic disease programs, including preclinical work, clinical trials, manufacturing, and Phase 3 readiness, as well as for working capital and general corporate purposes. The company reported preliminary cash, cash equivalents and marketable securities of $486.2 million as of September 30, 2025. SYRE trades on Nasdaq; the pre-funded warrants will not be listed.
Spyre Therapeutics announced it expects to report approximately $486.2 million in cash, cash equivalents and marketable securities as of September 30, 2025.
The figure is preliminary, has not been audited, and remains subject to completion of financial closing procedures. The company’s independent registered public accounting firm has not audited, reviewed, or performed procedures on this information and does not express assurance. The disclosure was provided under Item 2.02 of an 8-K and is furnished, not filed.
Spyre Therapeutics CFO Scott L. Burrows reported a sell-to-cover transaction tied to the settlement of restricted stock units. The filing shows 18,428 shares of common stock were sold at a weighted average price reported near $16.26, generated to satisfy tax withholding obligations arising from the settlement of 33,738 RSUs. Following the sale, the reporting person beneficially owns 97,994 shares outright.
The report also discloses an additional 67,476 RSUs that remain outstanding; those RSUs vest in two equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. The transaction is described as non-discretionary and solely for tax withholding.